Association of Checkpoint Inhibitor–Induced Toxic Effects With Shared Cancer and Tissue Antigens in Non–Small Cell Lung Cancer

Fiamma Berner; David Bomze; Stefan Diem; Omar Hasan Ali; Mirjam Fässler; Sandra S. Ring; Rebekka Niederer; Christoph Ackermann; Petra Baumgaertner; Natalia Pikor; Cristina Gil‐Cruz; Willem van de Veen; Mübeccel Akdiş; Sergey I. Nikolaev; Heinz Läubli; Alfred Zippelius; Fabienne Hartmann; Hung‐Wei Cheng; Gideon Hönger; Mike Recher; Jonathan W. Goldman; Antonio Cozzio; Martin Früh; Jacques Neefjes; Christoph Driessen; Burkhard Ludewig; Ahmed N. Hegazy; Wolfram Jochum; Daniel E. Speiser; Lukas Flatz

doi:10.1001/jamaoncol.2019.0402

Ask about this paper

Answers are grounded in this paper and cite their sources.

Abstract

These findings highlight a potential mechanism of checkpoint inhibitor-mediated autoimmune toxic effects and describe the association between toxic effects and response to therapy; such an understanding will help in controlling adverse effects, deciphering new cancer antigens, and further improving immunotherapy.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Berner et al. (2019) studied this question.

synapsesocial.com/papers/69d9a33d0d540cafc5836965 https://doi.org/10.1001/jamaoncol.2019.0402

View Full Paper

Ask AI

Bookmark

Share

Association of Checkpoint Inhibitor–Induced Toxic Effects With Shared Cancer and Tissue Antigens in Non–Small Cell Lung Cancer

Ask about this paper

Abstract

Discussion

Cite This Study

Association of Checkpoint Inhibitor–Induced Toxic Effects With Shared Cancer and Tissue Antigens in Non–Small Cell Lung Cancer

Ask about this paper

Abstract

Discussion

Cite This Study

Keep reading

Keep reading